With Q221 year-over-year growth up almost 46%, the US Spine market appears to be continuing on a skyward trajectory. However, as compared to Q219, Q221 saw growth of only +1.3%, reflecting ongoing COVID challenges. What’s really on the horizon for Spine? While the first half of 2021 has certainly looked much brighter than 2020, one big question remains: how big of an impact will the Delta variant surge have on the back half of the year?
Among the many topics covered in detail in our comprehensive Q221 Spine Market Recap* are:
- Complete Q221 Spine Market Overview
- SmartTRAK's Expert Analysis and Insights
- All Market News including Revenues, Data, Charts and Shares
- Top Players’ Results
- Q221 Regulatory Highlights
Medtronic* CFO Karen Parkhill reports that the Company experienced a slowdown starting at the end of July continuing into August. The Delta variant is expected to impact Medtronic’s US business next quarter particularly in businesses that are impacted by deferrable procedures such as Cardiac Diagnostics, ICDs, Pain Stim, Spine, and also in those businesses that require ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK has recently launched five new modules for 2021, including Pediatric Spine, Pediatric Trauma, Pediatric Extremities and Arthroscopic Technologies. Click here to see details of all the exciting new content now available on SmartTRAK.